Skip to Content
Merck
  • Targeted mutation of zebrafish fga models human congenital afibrinogenemia.

Targeted mutation of zebrafish fga models human congenital afibrinogenemia.

Blood (2014-02-21)
Richard J Fish, Corinne Di Sanza, Marguerite Neerman-Arbez
ABSTRACT

Mutations in the human fibrinogen genes can lead to the absence of circulating fibrinogen and cause congenital afibrinogenemia. This rare bleeding disorder is associated with a variable phenotype, which may be influenced by environment and genotype. Here, we present a zebrafish model of afibrinogenemia. We introduced targeted mutations into the zebrafish fga gene using zinc finger nuclease technology. Animals carrying 3 distinct frameshift mutations in fga were raised and bred to produce homozygous mutants. Using a panel of anti-zebrafish fibrinogen antibodies, fibrinogen was undetectable in plasma preparations from homozygous mutant fish. We observed hemorrhaging in fga mutants and reduced survival compared with control animals. This model will now serve in the search for afibrinogenemia modifying genes or agents and, to our knowledge, is the first transmissible zebrafish model of a defined human bleeding disorder.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fibrinogen from rat plasma, 60-80% protein (≥60% of protein is clottable)
Sigma-Aldrich
Fibrinogen from human plasma, 35-65% protein (≥90% of protein is clottable).
Sigma-Aldrich
Fibrinogen from human plasma, 50-70% protein (≥80% of protein is clottable)
Sigma-Aldrich
Fibrinogen from bovine plasma, Type I-S, 65-85% protein (≥75% of protein is clottable)